Patent ID: 7087390

Claim:
A method for evaluating a compound for the ability to modulate binding of a CAIP polypeptide with CD2, or a CAIP-binding fragment thereof, comprising: (i) combining (a) CD2, or the CAIP-binding fragment thereof, (b) a CAIP polypeptide having an amino acid sequence at least 80% identical to the sequence of SEQ ID NO:2, wherein the CAIP polypeptide is capable of binding to the intracellular domain of CD2, and (c) a compound, under conditions wherein in the absence of the compound, the CAIP polypeptide and CD2, or the CAIP-binding fragment thereof, are able to bind; and (ii) detecting the binding of the CAIP polypeptide and CD2, or the CAIP-binding fragment thereof, wherein a change in the binding in the presence of the compound relative to the binding in the absence of the compound is indicative of a modulation of binding.